Synthesis of Fluorinated Cannabinoids

The recent legalization of marijuana has sparked renewed interest in studying the health benefits of the non-psychoactive cannabinoids. Cannabidiol (CBO, 1, Figure 1) has emerged as a promising medicinal candidate due to its potential for the treatment of anxiety, and chronic pain. In 2018, the first CBD-containing drug, Epidio1ex, was approved by the FDA for the treatment of epilepsy. Despite its promise as a pharmaceutical, animal and human trials have found that CBD has low bioavailability and is prone to metaboHc degradation and excretion. This issue may be addressed through the synthesis of fluorinated derivatives, a commonly-utilized strategy in the pharmaceutical industry for increasing metabolic stability and modulating pharmacokinetics. The overall strategy of this project is to synthesize fluorinated CBD derivatives to make them more stable to oxidative degradation and excretion.

Faculty Supervisor:

Glenn Sammis


Brodie Thomson


Complex Biotech Discovery Ventures Ltd.




Professional, scientific and technical services


University of British Columbia



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects